Cited by 73Adrenal Hormones and DisordersEstrogen and related hormone effectsHormonal Regulation and Hypertension

Adrenal Suppression with Aminoglutethimide. I. Differential Effects of Aminoglutethimide on Glucocorticoid Metabolism as a Rationale for Use of Hydrocortisone12

SANTEN, RICHARD J., WELLS, SAMUEL A., RUNIC, SLOBODAN, GUPTA, CHHANDA, KENDALL, JOHN, RUDY, EDWARD B., SAMOJLIK, EUGENIUSZ·1977·The Journal of Clinical Endocrinology & Metabolism

Abstract

The morbidity resulting from surgical adrenalectomy in patients with metastatic breast carcinoma has limited the use of this procedure to highly selected patients. Consequently, a chemical method of adrenal inhibition was developed which used aminoglutethimide to block cholesterol to pregnenolone conversion and dexamethasone as replacement glucocorticoid. This regimen effectively lowered urinary free cortisol excretion but was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism of dexamethasone and reduced its bioavailability. Theoretically, replacement of dexamethasone with a glucocorticoid not subject to drug altered degradation would eliminate this drug interaction and simplify therapy. In order to determine whether hydrocortisone could be used, the metabolism and biological activity of this glucocorticoid was evaluated before and during aminoglutethimide administration. The plasma half-life, volume of distribution and metabolic clearance rate of hydrocortisone as determined by the single injection technique were not significantly altered by aminoglutethimide. The biopotency of hydrocortisone as reflected by its ability to suppress ACTH below basal levels was also retained during aminoglutethimide administration while that of dexamethasone was not. In order to evaluate the effectiveness of hydrocortisone in the aminoglutethimide regimen, a method was required for monitoring adrenal cortical function which was independent of glucocorticoid secretion. Plasma dehydroepiandrosterone-sulfate (DHA-S) levels were highly correlated (r – 0.79, P < .001) with urinary free cortisol excretion under basal and suppressed conditions. Plasma DHA-S was therefore used to establish the adrenal inhibiting effects of various doses of dexamethasone and hydrocortisone in patients receiving aminoglutethimide. A fixed dosage combination of 40 mg of hydrocortisone and 1000 mg of aminoglutethimide appeared to produce maximum suppression of DHA-S to levels 93% lower than basal. Negative nitrogen balance was not observed in patients receiving 20-60 mg of hydrocortisone along with aminoglutethimide, indicating a lack of major pharmacologic side effects of the administered glucocorticoid. A regimen for adrenal suppression using hydrocortisone and aminoglutethimide was developed which is simple and effective and should allow wide applicability without extensive endocrine monitoring in patients with metastatic breast carcinoma.

Integrity signals

Registry

Crossref · 10.1210/jcem-45-3-469

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aminoglutethimide is an inhibitor of CYP11A1 and CYP11B1 and was initially introduced as an antiepileptic medication.

    “Aminoglutethimide is an inhibitor of CYP11A1 and CYP11B1 and was initially introduced as an antiepileptic medication (322, 323).”

    From Adrenocortical carcinoma (2014) · cites this paper as [322]

Cited by

Sorted by citations

Authors
SANTEN, R. J., WELLS, S. A., RUNIC, S., GUPTA, C., KENDALL, J., RUDY, E. B., & SAMOJLIK, E.
Affiliations
  • Pennsylvania State University (US)
  • Oregon Health & Science University (US)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
1977-09
Volume
45
Issue
3
Pages
469-479
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2165422128
Cited by
73
References
0
Citations by year
2026: 2 · 2013: 1 · 2012: 1
FWCI
6.11
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
aminoglutethimide, cortisol, dexamethasone, adrenal suppression, glucocorticoid metabolism, drug interactions, dehydroepiandrosterone sulfate, urinary free cortisol, ACTH suppression, metastatic breast cancer, plasma half-life, metabolic clearance rate, negative nitrogen balance
MeSH terms
Adrenal Glands, Adrenocorticotropic Hormone, Aminoglutethimide, Breast Neoplasms, Castration, Dehydroepiandrosterone, Dexamethasone, Female, Humans, Hydrocortisone, Nitrogen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review